title: Effects of lipofectin-antigen complexes on major histocompatibility complex class I-restricted antigen presentation pathway in murine dendritic cells and on dendritic cell maturation.
abstract: We previously reported that exogenous antigens complexed with the cationic liposome lipofectin (LF) were efficiently presented via major histocompatibility complex (MHC) class I molecules on pulsed dendritic cells (DCs) in vitro. In the present study, we demonstrated that MHC class I-restricted antigen presentation on DC2.4 cells, a murine immature DC line, treated with LF-antigen complexes was remarkably suppressed through the inhibition of endocytosis, proteasome catalysis, and Golgi transport. We also found that LF did not influence expression of interleukin-12 p40 mRNA, MHC molecules, or co-stimulatory molecules in DC2.4 cells. These findings suggest that an antigen-loading procedure using LF could enhance delivery of exogenous antigens to the classical MHC class I pathway in DCs, but it does not initiate DC maturation.
authors.affiliation: Department of Biopharmaceutics, Kyoto Pharmaceutical University, Japan. okada@mb.kyoto-phu.ac.jp
authors.forename: N
authors.initials: N
authors.lastname: Okada
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: K
authors.initials: K
authors.lastname: Mori
authors.forename: Y
authors.initials: Y
authors.lastname: Masunaga
authors.forename: Y
authors.initials: Y
authors.lastname: Fujii
authors.forename: J
authors.initials: J
authors.lastname: Fujita
authors.forename: K
authors.initials: K
authors.lastname: Fujimoto
authors.forename: T
authors.initials: T
authors.lastname: Nakanishi
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
authors.forename: S
authors.initials: S
authors.lastname: Nakagawa
authors.forename: T
authors.initials: T
authors.lastname: Mayumi
authors.forename: T
authors.initials: T
authors.lastname: Fujita
authors.forename: A
authors.initials: A
authors.lastname: Yamamoto
mesh_terms: D000111:Acetylcysteine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D017951:Antigen Presentation / Q000187:drug effects*; D000941:Antigens / Q000737:chemistry / Q000494:pharmacology*; D020126:Brefeldin A / Q000494:pharmacology; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002738:Chloroquine / Q000494:pharmacology; D003571:Cytochalasin B / Q000494:pharmacology; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D008285:Major Histocompatibility Complex; D051379:Mice; D010047:Ovalbumin / Q000737:chemistry / Q000494:pharmacology; D010714:Phosphatidylethanolamines / Q000737:chemistry / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D000941:Antigens; D015395:Histocompatibility Antigens Class I; D010714:Phosphatidylethanolamines; C067713:lactacystin; D020126:Brefeldin A; D003571:Cytochalasin B; C020888:1,2-dielaidoylphosphatidylethanolamine; D002738:Chloroquine; D010047:Ovalbumin; D000111:Acetylcysteine